Reaction

Volvulus reporting signals

Last recalculated 2026-09-14T18:28:35.993900+00:00 · 2,302 reports · 58 co-occurring drugs

As of the last recalculation, Volvulus appears in 2,302 FAERS reports alongside 58 co-occurring drug terms. The strongest observed disproportionality signal is NEVIRAPINE (PRR 59.6).

Important: FAERS is a spontaneous, voluntary, unverified reporting system. PRR and ROR identify reporting patterns for investigation; they are not incidence rates and do not establish causation.

Drug	Co-reports	PRR	ROR
Nevirapine	58	59.6	60.0
Zidovudine	63	43.8	44.0
Raltegravir	59	33.1	33.2
Lopinavir And Ritonavir	44	29.9	30.0
Tenofovir Disoproxil Fumarate Tablets	21	22.2	22.2
Lamivudine Oral	60	22.0	22.0
Lamivudine	60	18.0	18.0
Lubiprostone	15	14.4	14.4
Tenofovir Disoproxil Fumarate	45	12.5	12.6
Linaclotide	36	12.4	12.4
Teduglutide	16	10.8	10.8
Baricitinib	10	9.4	9.4
Ritonavir 100 Mg	14	8.5	8.5
Dextrose	12	8.3	8.3
Dextrose Monohydrate	12	8.2	8.2
Ropinirole	13	7.7	7.7
Clozapine	101	7.6	7.6
Polyethylene Glycol	9	7.5	7.5
Rotigotine	12	7.5	7.5
Senna Leaf	19	7.5	7.5
Sennosides 8.6 Mg Tablets	17	7.4	7.4
Senna	17	7.3	7.3
Haloperidol Lactate	19	7.0	7.0
Timolol	9	6.8	6.8
Haloperidol	18	6.7	6.7
Sennosides	21	6.4	6.4
Pancrelipase	26	6.1	6.2
Memantine	9	6.0	6.0
Memantine Hydrochloride	9	6.0	6.0
Fulvestrant	21	5.8	5.8
Carbidopa And Levodopa	28	5.4	5.4
Niraparib	13	5.3	5.3
Rivastigmine	11	5.3	5.3
Amantadine	9	5.3	5.3
Risankizumab-Rzaa	46	5.2	5.2
Fesoterodine Fumarate	6	5.0	5.0
Eptinezumab-Jjmr	5	5.0	5.0
Rasagiline Mesylate	6	4.9	4.9
Pertuzumab	14	4.7	4.7
Adalimumab	320	4.6	4.6
Ivacaftor	4	4.6	4.6
Levodopa	6	4.5	4.5
Mirabegron	19	4.5	4.5
Peginterferon Beta-1A	6	4.1	4.1
Dornase Alfa	8	3.7	3.7
Vedolizumab	34	3.6	3.6
Upadacitinib	32	3.6	3.6
Irinotecan Hydrochloride	5	3.5	3.5
Osimertinib	12	3.4	3.4
Interferon Beta-1A	66	3.2	3.2
Oral Semaglutide	25	3.1	3.1
Crizotinib	4	2.8	2.8
Droxidopa	6	2.5	2.5
Palivizumab	3	1.8	1.8
Pimavanserin Tartrate	10	1.6	1.6
Erenumab-Aooe	9	1.5	1.5
Valbenazine	4	1.4	1.4
Tirzepatide	21	1.2	1.2

Related reactions

Data source: openFDA FAERS. See the OpenPV methodology and limitations.